Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Ambrisentan on Exercise Capacity in Fontan Patients

Trial Profile

The Effects of Ambrisentan on Exercise Capacity in Fontan Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Heart disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2014 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 09 Dec 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top